Business, energy, technology, markets and global industry news from Business News Today

BioMarin Pharmaceutical Inc.

PharmaDeviceNews BioMarin Pharmaceutical Inc.
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

BioMarin seeks FDA approval for Voxzogo in hypochondroplasia after Phase 3 success

BioMarin presents Voxzogo skull growth research and Phase 3 hypochondroplasia data. Examine clinical evidence, FDA reviews and 2027 prospects.

Read More
BioMarin and n-Lorem Foundation are advancing early research into a potential antisense medicine targeting the RNU4-2 variant associated with ReNU syndrome, a newly identified rare neurodevelopmental disorder. Representative image.
Pharma & Biotech

How BioMarin and n-Lorem plan to develop an antisense therapy for ReNU syndrome

BioMarin and n-Lorem launch a preclinical antisense program targeting the RNU4-2 variant behind most ReNU syndrome cases.

Read More
Pharma & Biotech

Could BMN 333 help BioMarin reset expectations in achondroplasia treatment?

Find out how BioMarin’s VOXZOGO and BMN 333 data could reshape rare bone disorder treatment as competition intensifies.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More